Organigram Global (OGI) Cash from Discontinued Operations (2018 - 2026)
Organigram Global (OGI) posted quarterly Cash from Discontinued Operations of 16606201222.71 for Q1 2026, down 43.67% year-on-year from 29481592612.3 in Q1 2025, and down 144619174.12% on a QoQ basis from 11482.7 in Q4 2025.
Organigram Global (OGI) Cash from Discontinued Operations (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Cash from Discontinued Operations for 7 consecutive years, with 16606201222.71 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Discontinued Operations fell 43.67% year-over-year to 16606201222.71 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28164575453.97 (up 34.32% YoY) and the FY2021 annual result came in at 5132000.0, changed N/A from the prior year.
- Cash from Discontinued Operations slipped to 16606201222.71 in Q1 2026 per OGI's latest filing, from 11482.7 in the prior quarter.
- Over the last five years, Cash from Discontinued Operations for OGI reached as high as 2992.25 in Q4 2024 and fell as low as 16606201222.71 in Q1 2026.
- A 3-year average of 7041143863.49 and a median of 5779185619.5 in 2025 frame the typical range for Cash from Discontinued Operations.
- Annual changes were most pronounced in 2025 — Cash from Discontinued Operations slumped 283.75% — and 2026, when it sank 43.67%.
- Year by year, Cash from Discontinued Operations stood at 2992.25 in 2024, then sank by 283.75% to 11482.7 in 2025, then plunged by 144619174.12% to 16606201222.71 in 2026.
- According to Business Quant data, Cash from Discontinued Operations over the past three periods registered 16606201222.71, 11482.7, and 11558359756.31 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.15 Bn | 20.99 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | - |
| 10 | Organigram Global | 122.43 Mn | 155.50 Mn | 28.97 Mn | -16.61 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.61 Bn |
| Mar 31, 2026 | -16.61 Bn |
| Dec 31, 2025 | -11,482.70 |
| Dec 31, 2025 | -11,482.70 |
| Mar 31, 2025 | -11.56 Bn |
| Mar 31, 2025 | -11.56 Bn |
| Dec 31, 2024 | -2,992.25 |
| Dec 31, 2024 | -2,992.25 |
| May 31, 2021 | -20.89 Bn |
| May 31, 2021 | -20.89 Bn |
| Feb 28, 2021 | -10.43 Bn |
| Feb 28, 2021 | -10.43 Bn |
| Nov 30, 2020 | 294.00 Mn |
| Nov 30, 2020 | 294.00 Mn |
| May 31, 2020 | 6,106.93 |
| May 31, 2020 | 6,106.93 |
| Feb 29, 2020 | 11.34 Bn |
| Feb 29, 2020 | 11.34 Bn |
| Aug 31, 2019 | 15,722.00 |
| Aug 31, 2019 | 15,722.00 |